Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 15-23
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Table 2 Recent therapeutic effects in the two groups
Group | CR | PR | SD | PD | DCR |
Observation group (n = 47) | 0 | 11 (23.40) | 17 (36.17) | 19 (40.43) | 28 (59.57) |
Control group (n = 47) | 0 | 10 (21.28) | 16 (34.04) | 21 (44.68) | 26 (55.32) |
χ2 | 0.174 | ||||
P value | 0.677 |
- Citation: Zhou DB, Cheng J, Zhang XH. Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis. World J Clin Cases 2024; 12(1): 15-23
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/15.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.15